Cookies on this website
We use cookies to ensure that we give you the best experience on our website. If you click 'Continue' we'll assume that you are happy to receive all cookies and you won't see this message again. Click 'Find out more' for information on how to change your cookie settings.

<jats:title>ABSTRACT</jats:title><jats:p>Malaria treatment in Southeast Asia is threatened with the emergence of artemisinin-resistant<jats:named-content xmlns:xlink="http://www.w3.org/1999/xlink" content-type="genus-species" xlink:type="simple">Plasmodium falciparum</jats:named-content>. Genome association studies have strongly linked a locus on<jats:named-content xmlns:xlink="http://www.w3.org/1999/xlink" content-type="genus-species" xlink:type="simple">P. falciparum</jats:named-content>chromosome 13 to artemisinin resistance, and recently, mutations in the kelch13 propeller region (<jats:italic>Pfk-13</jats:italic>) were strongly linked to resistance. To date, this information has not been shown in Indian samples.<jats:italic>Pfk-13</jats:italic>mutations were assessed in samples from efficacy studies of artemisinin combination treatments in India. Samples were PCR amplified and sequenced from codon 427 to 727. Out of 384 samples, nonsynonymous mutations in the propeller region were found in four patients from the northeastern states, but their presence did not correlate with ACT treatment failures. This is the first report of<jats:italic>Pfk-13</jats:italic>point mutations from India. Further phenotyping and genotyping studies are required to assess the status of artemisinin resistance in this region.</jats:p>

Original publication

DOI

10.1128/aac.04632-14

Type

Journal

Antimicrobial Agents and Chemotherapy

Publisher

American Society for Microbiology

Publication Date

05/2015

Volume

59

Pages

2548 - 2553